CLINICAL_TRIALS
trial_result
· 2024-05-16
Clinical Trial Update: Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD) [Phase 2]
Summary
Phase 2 BEHOLD study assessing safety, tolerability, and preliminary activity of UBX1325 in diabetic macular edema; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Unity Biotechnology, Inc. | Conditions: Diabetic Macular Edema (DME) | Phase 2 | Status: COMPLETED | Results posted: 2024-05-16